[Orphan drugs and metabolic disorders]

Area of Science:

• Biochemistry
• Genetics
• Neurology

Context:

• Orphan diseases, defined as conditions affecting fewer than 1 in 5,000 people, present unique challenges in drug development due to small patient populations.
• Metabolic disorders, often genetically based, frequently fall under the orphan disease classification, necessitating specialized and often costly treatments.
• The financial disincentives for developing and marketing drugs for rare conditions lead to the concept of 'orphan drugs'.

Purpose:

• To discuss the treatment of three distinct orphan metabolic diseases impacting the central nervous system.
• To highlight the use of specific orphan drugs in managing these rare conditions.
• To present case examples of successful therapeutic interventions for niche patient groups.

Summary:

• The study details the treatment of three orphan metabolic diseases: tetrahydrobiopterin synthesis deficiency, N-acetylglutamate synthetase deficiency, and cystathionine synthetase deficiency.
• Tetrahydrobiopterin is used to treat neurotransmitter deficiency caused by its synthesis deficit.
• N-carbamyl glutamate addresses hyperammonaemia and cerebral edema in N-acetylglutamate synthetase deficiency, while Betaine manages hyperhomocysteinemia in cystathionine synthetase deficiency.

Impact:

• Demonstrates effective therapeutic strategies for rare metabolic disorders with severe neurological consequences.
• Highlights the critical role of targeted orphan drugs in managing conditions with limited treatment options.
• Provides valuable insights into the clinical application of specific treatments for genetically defined orphan diseases.